NCT04987476

Brief Summary

The aim is to describe at the cellular level the heterogeneity of rhabdoid tumors, and identify how this diversity influences resistance to treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Mar 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 31, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 3, 2021

Completed
8 months until next milestone

Study Start

First participant enrolled

March 31, 2022

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 21, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 21, 2025

Completed
Last Updated

November 20, 2025

Status Verified

October 1, 2025

Enrollment Period

2.9 years

First QC Date

July 31, 2021

Last Update Submit

November 17, 2025

Conditions

ATRT

Keywords

ATRTSMARCB1single-cell RNAseq

Outcome Measures

Primary Outcomes (1)

  • Intra-tumor heterogeneity

    Identification of cell clusters - mean expression (RPKM unit) of gene set signtaures in each bioinformatically defined cluster

    Inclusion

Secondary Outcomes (3)

  • Cell clusters recurrent from one sample to the other

    Inclusion

  • Naming of potential targetable gene

    Inclusion

  • Identification of cytotoxic cells

    Inclusion

Study Arms (1)

ATRT

Children affected by an ATRT at time of surgical resection

Biological: analyzes in singles cells

Interventions

analyzes in singles cellsBIOLOGICAL

genome expression analyzes in single cells

ATRT

Eligibility Criteria

AgeUp to 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Children having or likely having a rhabdoid tumor according to clinical and radiological features

You may qualify if:

  • Aged 0-17 years old
  • having a rhabdoid tumor according to clinical and radiological features Or likely having a rhabdoid tumor according to clinical and radiological features
  • surgical resection in standard care
  • sufficient material for both diagnosis and experimental procedures
  • parents' agreement

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institut Curie

Paris, 75005, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Tumor samples

Study Officials

  • Kevin Beccaria, MD, PhD, Pr

    APHP Assistance Publique des Hôpitaux de Paris

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 31, 2021

First Posted

August 3, 2021

Study Start

March 31, 2022

Primary Completion

February 21, 2025

Study Completion

February 21, 2025

Last Updated

November 20, 2025

Record last verified: 2025-10

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)